Industry Strength Score
37/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
ABIVAX SA (2X1.DE) Stock Price & Overview
FRA:2X1 • FR0012333284
Current stock price
95.4 EUR
-1.1 (-1.14%)
Last:
The current stock price of 2X1.DE is 95.4 EUR. Today 2X1.DE is down by -1.14%. In the past month the price increased by 7.19%.
2X1.DE Key Statistics
1-Month Range88.7 - 108.8
Current 2X1.DE stock price positioned within its 1-month range.
- Market Cap
- 7.564B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.83
- Dividend Yield
- N/A
2X1.DE Stock Performance
Today
-1.14%
1 Week
-2.40%
1 Month
+7.19%
3 Months
+1.17%
Longer-term
6 Months +5.18%
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
2X1.DE Stock Chart
2X1.DE Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to 2X1.DE.
Chartmill TA Rating
Chartmill Setup Rating
2X1.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to 2X1.DE. While 2X1.DE seems to be doing ok healthwise, there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
2X1.DE Earnings
On March 23, 2026 2X1.DE reported an EPS of -3.24 and a revenue of 2.48M. The company missed EPS expectations (-112.47% surprise) and beat revenue expectations (21.72% surprise).
Next Earnings DateMay 25, 2026
Last Earnings DateMar 23, 2026
PeriodQ4 / 2025
EPS Reported-€3.24
Revenue Reported2.483M
EPS Surprise -112.47%
Revenue Surprise 21.72%
2X1.DE Forecast & Estimates
14 analysts have analysed 2X1.DE and the average price target is 132.47 EUR. This implies a price increase of 38.86% is expected in the next year compared to the current price of 95.4.
For the next year, analysts expect an EPS growth of 81.52% and a revenue growth -10.7% for 2X1.DE
Analysts
Analysts85.71
Price Target132.47 (38.86%)
EPS Next Y81.52%
Revenue Next Year-10.7%
2X1.DE Financial Highlights
Over the last trailing twelve months 2X1.DE reported a non-GAAP Earnings per Share(EPS) of -4.83. The EPS decreased by -72.93% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-336.10M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -57.52% | ||
| ROE | -73.84% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-116%
Sales Q2Q%-55.93%
EPS 1Y (TTM)-72.93%
Revenue 1Y (TTM)N/A
2X1.DE Ownership
Ownership
Inst Owners37.95%
Shares79.29M
Float76.43M
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
2X1.DE Industry Overview
2X1.DE operates in the Biotechnology sub-industry within the Health Care sector. This group contains 52 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
78/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
23%
Outperformed 23% of sub-industries
3 Month Rank
21%
Outperformed 21% of sub-industries
6 Month Rank
37%
Outperformed 37% of sub-industries
Industry Fundamentals & Breadth
- Members
- 52
- New Highs
- 1.9%
- New Lows
- 11.5%
- Average ROE
- 26.7%
- Average Profit Margin
- 29.7%
- Average Operating Margin
- 25.9%
- Average P/E
- 38.1
- Average Fwd P/E
- 30.1
- Average Debt/Equity
- 0.0
2X1.DE Competitors/Peers
The largest stocks on the EU markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 28.24 | 41.394B | ||
| 1AE | ARGENX SE | 28.63 | 41.369B | ||
| 22UA | BIONTECH SE-ADR | N/A | 21.963B | ||
| ABVX | ABIVAX SA | N/A | 7.576B | ||
| GXE | GALAPAGOS NV | N/A | 1.6B | ||
| GLPG | GALAPAGOS NV | N/A | 1.597B | ||
| NANO | NANOBIOTIX | N/A | 1.372B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 1.005B | ||
| PHARM | PHARMING GROUP NV | 46.56 | 1.001B | ||
| PHGN | PHARMING GROUP NV | 46.71 | 1.001B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 954.74M | ||
| IVA | INVENTIVA SA | N/A | 895.23M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 2X1.DE
Company Profile
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 69 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Company Info
IPO: 2015-06-26
ABIVAX SA
7-11 Boulevard Haussmann
Paris ILE-DE-FRANCE FR
Employees: 69
Phone: 33153830963
ABIVAX SA / 2X1.DE FAQ
What does ABIVAX SA do?
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 69 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
What is the current price of 2X1 stock?
The current stock price of 2X1.DE is 95.4 EUR. The price decreased by -1.14% in the last trading session.
Does ABIVAX SA pay dividends?
2X1.DE does not pay a dividend.
What is the ChartMill technical and fundamental rating of 2X1 stock?
2X1.DE has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting 2X1 stock to perform?
14 analysts have analysed 2X1.DE and the average price target is 132.47 EUR. This implies a price increase of 38.86% is expected in the next year compared to the current price of 95.4.
What is the GICS sector and industry of 2X1 stock?
ABIVAX SA (2X1.DE) operates in the Health Care sector and the Biotechnology industry.